Le Lézard
Classified in: Health
Subject: AWD

Ramzan M. Zakir, M.D., F.A.CC., FSCAI is recognized by Continental Who's Who


NEW BRUNSWICK, N.J., Dec. 11, 2017 /PRNewswire/ -- Ramzan M. Zakir, M.D., F.A.CC., FSCAI is recognized by Continental Who's Who as a Pinnacle Lifetime Member in the field of Medicine at Heart & Vascular Institute of Central New Jersey in recognition of his role as Interventional Cardiologist.      

Dedicated to offering their patients quality, comprehensive health care, Heart and Vascular Institute of Central Jersey is committed to serving their clients. In this capacity, the team at Heart and Vascular "believe in developing a strong relationship with our patients based on compassion, mutual respect and understanding."   A frontrunner in the medical industry, the healthcare facility is equipped with the latest innovations in technology and provides, "exceptional diagnostic services to help initiate a focused, personalized treatment plan to improve your health condition."  Offering a wide array of services to their clients, the facility specializes in Coronary Artery Disease, Congestive Heart Failures, Valvular Heart Disease, Cardiomyopathies, and more.  In addition, they are specialized in various diagnostic testing including, Echocardiograms and Stress tests.

Practicing since 2009, Dr. Zakir has performed thousands of successful angioplasty procedures in his role of internventional cardiologist, as well as expanding his practice to peripheral vascular diseases. He is board certified in cardiology, vascular medicine, nuclear medicine, and has recently obtained his PVI certificate for vascular ultrasound. Heart and Vascular Institute of Central Jersey is where Dr. Zakir can assess the needs of his patients prior to performing complex coronary interventions, chronic total occlusions, carotid artery stenting and endovascular interventions for patients with peripheral vascular diseases as well as venous ablations for venous insufficiency.

Throughout the course of his education and training, Dr. Zakir attended Rutgers College and completed both his internship and residency at UMDNJ ? New Jersey Medical School, and served as Chief Medical Resident through the program at Hackensack University Hospital. He is Board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology, Echocardiography Nuclear Cardiology and Endovascular. He also speaks Urudu and Punjabi Hindi as well as English.

Clinical Assistant Professor of Medicine at Rutgers Medical School ? Robert Wood Johnson University Hospital, Dr. Zakir is involved in research and fellow training. Director of the Peripheral Vascular Program at Saint Peter's University Hospital, Dr. Zakir is the principal investigator of several clinical trials to enhance the management of patients with peripheral arterial disease. He previously served as the Director of Transradial Catherization at Robert Wood Johnson University Hospital, from 2011 to 2016.

To further his professional development, Dr. Zakir is a Fellow of the American College of Cardiology, a Fellow of the Society for Cardiac Angiography and Intervention, and a member of the Police Defense Foundation as well as Health Forces for Police. He has contributed several articles to renowned medical publications.

When not working, Dr. Zakir enjoys tennis, basketball, football, and rooting for the New York Jets, Knicks and Yankees. He dedicates this recognition to his father, Mirza, and to Saud Sadiq.

For more information, visit www.NJHeartandvascular.com.

Contact: Katherine Green, 516-825-5634, [email protected]

SOURCE Continental Who's Who


These press releases may also interest you

at 18:30
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four...

at 18:16
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 17:56
The Canadian Cancer Society commends the increases in taxes on tobacco and e-cigarettes in today's federal budget.  The budget increases tobacco taxes by $4.00 per carton of 200 cigarettes effective at midnight, and increases e-cigarette taxes by 12%...

at 17:45
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

at 17:31
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...



News published on and distributed by: